D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
SGMOQ holding history
Sangamo Therapeutics, Inc in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SGMOQ overviewAll 13F holders of SGMOQFull Q2 2026 holdings
- Shares (Q3 2024)
- 0
- Sold out in Q3 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 14
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2024 | 0 | $0 | 0.0% | −1,165,993−100.0% | Sold out | Holders |
| Q2 2024 | 1,165,993 | $417.8K | <0.1% | −1,901,442−62.0% | Reduced | Holders |
| Q1 2024 | 3,067,435 | $2.06M | <0.1% | −1,616,538−34.5% | Reduced | Holders |
| Q4 2023 | 4,683,973 | $2.54M | <0.1% | +2,175,388+86.7% | Added | Holders |
| Q3 2023 | 2,508,585 | $1.50M | <0.1% | +124,609+5.2% | Added | Holders |
| Q2 2023 | 2,383,976 | $3.10M | <0.1% | +590,789+32.9% | Added | Holders |
| Q1 2023 | 1,793,187 | $3.16M | <0.1% | +417,358+30.3% | Added | Holders |
| Q4 2022 | 1,375,829 | $4.32M | <0.1% | +171,197+14.2% | Added | Holders |
| Q3 2022 | 1,204,632 | $5.90M | <0.1% | +48,402+4.2% | Added | Holders |
| Q2 2022 | 1,156,230 | $4.79M | <0.1% | +401,463+53.2% | Added | Holders |
| Q1 2022 | 754,767 | $4.38M | <0.1% | +200,022+36.1% | Added | Holders |
| Q4 2021 | 554,745 | $4.16M | <0.1% | +512,831+1,223.5% | Added | Holders |
| Q3 2021 | 41,914 | $378.0K | <0.1% | +17,269+70.1% | Added | Holders |
| Q2 2021 | 24,645 | $295.0K | <0.1% | −47,063−65.6% | Reduced | Holders |
| Q1 2021 | 71,708 | $899.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.